Please login to the form below

Not currently logged in
Email:
Password:

chronic spontaneous urticaria

This page shows the latest chronic spontaneous urticaria news and features for those working in and with pharma, biotech and healthcare.

Novartis funds chronic urticaria app and patient community

Novartis funds chronic urticaria app and patient community

Novartis is funding a new mobile app and website that aims to create an online support community for patients with chronic urticaria, or hives. ... Planned features for the app will allow patients to follow chronic urticaria associations and

Latest news

  • 90TEN and ICG win market research award at Communiqué 2015 90TEN and ICG win market research award at Communiqué 2015

    Their'Wheals of Despair'campaign, created for Novartis UK, focused on chronic spontaneous urticaria (CSU) - a condition that was until recently a mystery to many doctors and almost completely unknown to

  • NICE set to back Novartis' Xolair for skin condition CSU NICE set to back Novartis' Xolair for skin condition CSU

    Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria. ... NICE is poised to recommend Novartis' Xolair as an add-on treatment option for severe chronic spontaneous urticaria (CSU) in adults after the company

  • Novartis' dermatology plans advance with Xolair approval Novartis' dermatology plans advance with Xolair approval

    Green light for use in chronic spontaneous urticaria. Novartis' asthma drug Xolair has been approved in Europe for a new indication, the treatment of a severe form of hives known as ... chronic spontaneous urticaria (CSU).

  • CHMP backs Xolair for severe hives CHMP backs Xolair for severe hives

    The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Xolair (omalizumab) for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU). ... Chronic urticaria affects around 1 per cent of the

  • Novartis' omalizumab effective in chronic skin disease Novartis' omalizumab effective in chronic skin disease

    The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the ... Novartis filed for approval of omalizumab a few weeks ago as a

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics